Journal of Surgery and Anesthesia

Recent advance in surgery on end -stage constrictive Pericarditis

11^th International Conference on Surgery

September 01, 2022 | Webinar

Ramachandran Muthiah

Morning Star hospital, India

Scientific Tracks Abstracts: J Surg Anesth

Abstract:

The pericardium increases the cardiac efficacy by limiting the distance of cardiac chambers, protects the heart by reducing external friction and provide a barrier to extension of infection and malignancy. In constrictive pericarditis, the thickened, fibrous pericardium that form a non-complaint shell around the heart, inhibits the diastolic filling. “End-stage” constrictive pericarditis has posed a diagnostic dilemma since it presented with features of right-sided heart failure. Etiology remains unknown in majority of case and inflammatory process play a central role in its development. Currently, pericardiectomy is the only accepted curative treatment for improving cardiac hemodynamics in constrictive pericarditis. Pericardium resection (or pericardial stripping) is a surgical procedure where the entire pericardium is pealed away from the heart. In advanced (end-stage) constrictive pericarditis, pericardiectomy may not offer a cure or desired long term results. Amniotic stem cell therapy consisting of either stem cells with extracellular matrix or extracellular matrix alone in the form of human amniotic membrane allograft, an emerging anti-inflammatory and antifibrotic treatment and four human allograft membranes were topically placed over the right atrium, right ventricle and left ventricle prior to closure. Stem cells promote cardiac cell regeneration through direct and paracrine factors, decreases cardiac muscle apoptosis and improves blood supply to ischemic regions of the heart

Biography :

Ramachandran Muthiah is a working as a Doctor in Morning Star hospital, Kanyakumari District, India and he has done many researches in this field.